|
|
Article: Data From Preclinical Studies Examining Effect of ATN-161 on Organ and Skeletal Metastases of Breast Cancer Presented at American Association for Cancer Research Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- March 29, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, March 29 /PRNewswire/ -- Attenuon, LLC, a private pharmaceutical company developing a new generation of cancer therapies, announced that Dr. Shafaat Rabbani of McGill University will give an oral presentation describing preclinical data demonstrating that treatment with ATN-161 significantly slowed the progression of primary tumors and completely inhibited the growth of well-established bone metastases. This presentation will be delivered during a mini-symposium on novel therapeutic agents at the Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida on Tuesday, March 30th, 2004.
"We are greatly encouraged by the ...